We have developed a new bioassay for thyrotropin (TSH) in human serum to evaluate bioactivity in normal individuals and patients with different degrees of primary hypothyroidism. Unpurified TSH in serum showed no stimulation of cyclic AMP production in cultured FRTL-5 rat thyroid cells, but after immunopurification showed potent stimulatory activity. Immunoaffinity purification permitted up to 400-fold concentration of serum TSH, allowing bioactivity measurements even in certain normal sera. The limit of detection in the FRTL-5 bioassay was 10 isU of human TSH per 0.5 ml incubate, and half-maximal responses for standard human TSH was 102±26 (± SE) gU/ 0.5 ml. Immunoaffinity-purified serum TSH varied in bioactivityto-immunoactivity (B/I) ratios from < 0.25 to 1.21 among four euthyroid subjects and eight primary hypothyroid patients. An inverse correlation was found between B/I ratios of immunopurified basal TSH and the serum-free T4 (r =-0.7237, P < 0.01), T4 (r = -0.6650, P < 0.05), and T3 (r =-0.6382, P < 0.05). B/I ratios of immunopurified TSH from three hypothyroid patients before and after acute stimulation by thyrotropinreleasing hormone showed no significant change, despite major changes in serum TSH. In summary, the present study shows an inverse relationship between the metabolic status of an individual and the intrinsic bioactivity of TSH.
Introduction
The development of radioimmunoassay methods for measurement of human thyrotropin (TSH)1 has permitted determination of serum concentrations in various physiologic and pathophysiologic conditions (1, 2) . Unfortunately, there have only been a few reports comparing TSH bioactivity (B) to its immunoactivity (I) . Early in vivo TSH bioassays in rodents were of limited sensitivity and precision, and were affected by possible variations of metabolic clearance rate in the animal (3) . Because of these limitations such bioassays were only applied to the measurement of very high TSH concentrations in certain patients with primary hypothyroidism, and yielded highly variable results (4, 5) .
The development of a sensitive cytochemical method has permitted estimation of TSH bioactivity in small volumes of unfractionated serum from normal individuals as well as from those with primary and central hypothyroidism (6) (7) (8) . However, the cytochemical bioassay is technically difficult and has only been employed by a few groups. Moreover, the dose-response curves show a shallow slope with a low index of precision (3) . Finally, it has not yet been established that this assay, like earlier bioassays employing unfractionated serum, is free from interference by non-TSH stimulators or inhibitors, such as thyroidstimulating and thyroid-inhibiting immunoglobulins (9) .
We have previously reported immunoaffinity techniques that permitted purification and concentration of TSH from human serum (10). Such purification has been applied previously to a bioassay method employing stimulation ofadenylate cyclase activity in human thyroid membranes (1 1-13) . Using these methods we have shown that one euthyroid patient with a TSH of high molecular weight and seven patients with hypothalamic hypothyroidism had decreased thyrotropic bioactivity and that one patient with a TSH-secreting pituitary tumor had increased thyrotropic bioactivity when compared with patients with primary hypothyroidism (1 1-13). However, human thyroid membranes are not readily available, and different preparations show widely variable dose-response characteristics.
Recently a clonal line derived from functional rat thyroid cells (FRTL-5) has been widely applied to the measurement of thyroid-stimulating and/or growth-promoting immunoglobulins in human serum (14, 15) . Although these cells have been used for the bioassay of different pituitary TSH preparations (16) , they have not previously been employed for the measurement of TSH bioactivity in animal or human serum.
In the present study we describe a method for the bioassay of TSH immunopurified from the serum of normal individuals and patients with different degrees of primary hypothyroidism. Because of the sensitivity and precision of this new bioassay, we have been able to show a highly significant inverse relationship between serum thyroid hormone concentrations and the intrinsic bioactivity of TSH, and a direct relationship between the serum TSH concentrations and its bioactivity.
Methods
Subjects. Four normal individuals and eight patients were included in the study. The selection of subjects was based on the availability of relatively large amounts of serum (15- at three to four dilutions and the results were calculated using a fourparameter sigmoidal program (20) .
Immunopurification ofserum TSH. Partial purification ofserum TSH was performed by immunoaffinity chromatography on an anti-a column as previously described (10). Serum (15-250 ml) was centrifuged at 102,000 g for 1 h at 4°C, and was applied to the column overnight at 4°C. TSH was eluted with 3.0 M guanidine-HCl, pH 3.2. The eluates were directly transferred into dialysis bags (PA-10; Bio-Molecular Dynamics, Beaverton, OR) and extensively dialyzed against hypotonic Hanks' balanced salt solution (HBSS). The samples were then concentrated to a final volume of0.5-1 ml by vacuum dialysis (Micro-ProDiCon dialysis/concentrator unit; Bio-Molecular Dynamics) against the same buffer and stored at -20°C up to 2 wk before being tested for bioactivity. Between experiments, any residual tightly bound material was eluted with 6.0 M guanidine-HCl, pH 3.2. The TSH binding capacity per milliliter of antibody-coupled agarose was 6,000 MU of TSH in terms of the 2nd IRP, which was equivalent to 0.53 Mg ofpurified TSH (CalbiochemBehring Corp., La Jolla, CA) or 4.0 Mg of crude TSH (National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases [NIADDK] Hormone Distribution Program Reference Preparation 1). During purification and concentration of serum samples, 40-60% of the original immunoreactive TSH was recovered. Of the TSH lost, 10-30% was in the fraction not bound to the column, 5-15% in the 6 M guanidine wash and 10-30% in the subsequent handling of the 3 M guanidine eluate. There were no systematic differences in the proportions of immunoreactive TSH recovered at various purification steps among the various patient groups. The current method of concentration ofeluted TSH was more convenient than the lyophilization (11) (12) (13) , and yielded the same recovery ofthe original material as the latter without affecting bioactivity. The TSH in the 6 M guanidine eluates that were tested for bioactivity was handled as described for 3 M guanidine eluates, whereas the TSH in the fractions not bound to the column was lyophilized, reconstituted in hypotonic HBSS, and dialyzed against the same buffer before bioassay. The possibility of antibody leakage in eluates or dissociation of TSH into its a and (B subunits during purification was ruled out as previously described ( 12) .
TSH bioassay. The FRTL-5 rat thyroid cell strain was kindly provided by Dr. L. D. Kohn and Dr. C. Rotella (NIADDK). Details of the derivation and characteristics of this clonal line of functional rat thyroid epithelial cells have been described in previous reports (21, 22) . Cells were maintained in Coon's modified Ham's F12 medium containing 5% calf serum (Gibco, Grand Island, NY), 100 U/ml penicillin, and 100
Ag/ml streptomycin and a supplement of six hormones (6H) consisting of 10 mU/ml bovine TSH (Armour Pharmaceutical Co., Tarrytown, NY); 10 Atg/ml bovine insulin (Sigma Chemical Co., St. Louis, MO); 10-8 M hydrocortisone (Sigma Chemical Co.); 5 ,g/ml transferrin (Sigma Chemical Co.); 10 ng/ml glycyl-L-histidyl lysine acetate, (Sigma Chemical Co.); and 10 ng/ml somatostatin (Calbiochem-Behring Corp.). Cells were detached, plated, and grown by established techniques (21, 22). The bioassay procedure used is a modification ofpreviously described methods (23) (24) (25) . Cells to be utilized for bioassay were split from confluent 10-cm Petri dishes, suspended as individual cells in 6H media, and seeded at a density of 1-2 X 10' cells/ml in 24-well tissue culture plates. Media was changed every 3 d, and when confluent the cells were switched to the same medium without TSH (5H). After 7-10 d the cells were washed with isotonic HBSS, and the assay was then performed by incubating the cells with TSH diluted in 0.5 ml of hypotonic HBSS (5 mM KCl, TSH bioactivity was determined as the cAMP production in stimulated FRTL-5 cells. The detection limit of the assay was 10 MU/well of hTSH WHO 2nd IRP, and the intra-assay coefficient of variation was 9%. Dose-response curves of the different reference preparations were analyzed with the four-parameter logistic model suggested by De Lean et al. (20) , allowing comparisons of biopotency and parallelism. The individual bioactivity of the immunoaffinity-purified samples was evaluated using the 2nd IRP as the internal standard and calculated from the four-parameter logistic equation:
where y is the response, x is the arithmetic dose, a is the response when 7 .4, containing 0.02% sodium azide differences in recovery were found when different concentrations of standard human TSH (Calbiochem-Behring Corp.) ranging from 200 to 2,000 uU/ml diluted in constant volumes of TSH-free human serum (unbound fraction of immunoaffinity-purified serum from normal subjects) were immunoaffinity purified. (c) When the same serum sample obtained from one single plasmapheresis was immunoaffinity purified in two separate occasions, the recovery ranged between 40 and 60%, whereas the bioactivity was the same with no evidence of selective recovery of high vs. low B/I TSH. (d) When human TSH (CalbiochemBehring Corp.) was immunoaffinity purified, dialyzed, and subsequently handled exactly as the patients' samples, we did not find any significant change in its bioactivity when compared with the nonimmunoaffinitypurified standard. (e) The presence of unknown inhibitory or non-TSH stimulatory factors in immunoaffinity-purified serum TSH was ruled out on the basis of the following mixing experiment. Similar amounts of TSH samples from patients with low and high B/I ratios were mixed with both high and low amounts of standard human TSH (CalbiochemBehring Corp.). No modification of standard TSH bioactivity was detected other than the one predicted (i.e., the TSH standard activity was additive with the endogenous TSH activity).
Statistics. Pearson's correlation coefficient was calculated between the TSH B/I and serum values for FT4, T4, T3, and TSH measured by radioimmunoassay. The TSH dose-response curves for radioimmunoassay were linearized using a logit-log transformation, and the parallelism of curves was tested with Student's t test.
Results
The typical dose-response curves of the FRTL-5 bioassay to nonimmunoaffinity-purified bovine and human TSH pituitary preparations, obtained using a four-parameter logistic model are shown in Fig. 1 . The biopotencies of the tested preparations were similar, with half-maximal responses (ED50) for crude human TSH (2nd IRP)-purified human TSH, and crude bovine TSH being 102±26 ,U/0.5 ml (± SE), 106±30 AU/0.5 ml, and 131±41 ,uU/0.5 ml, respectively. These values were not statistically different.
Cross-reactivity in the bioassay was tested for the following hormones and subunits: hTSH a-subunit, 50-1,000 ng (NIADDK, hTSH a-1); hTSH (i-subunit, 50-2,000 ng (NIADDK, hTSH ,B-2); hLH, 50-1,000 ng (NIADDK, hLH-I-3); hFSH, 50-1,000 ng (NIADDK, hFSH-I-6); hCG a-subunit, 50-1,000 ng (NICHD and NIADDK, hCG a-CR-1 19); and hCG fl-subunit, 50-1,000 ng (NICHD and NIADDK, hCG fy-CR-123). No stimulation of cAMP was demonstrated other than that attributable to known TSH contamination of the hLH I-3 (40 ttU/Mg) and hFSH 1-6 (120 ,U/,ug) preparations. TRH, tested in the dose range of 10-12 M to 10-6 M, showed no intrinsic stimulation in this assay. Unpurified samples of serum TSH showed no stimulation of cAMP in the FRTL-5 bioassay even after dialysis against the hypotonic assay buffer. When increasing amounts of dialyzed serum from normal and primary hypothyroid patients were added to known quantities of immunoaffinity-purified hTSH, there was a progressive decrease in cAMP production at each TSH concentration of the immunopurified standard (data not shown). The inhibition was 60% when 10% ofdialyzed serum was present in the incubation medium and > 80% in the presence of 40% dialyzed serum. No significant differences were detected between normal and primary hypothyroid serum. The inhibitory factors were not affected by preabsorption of the serum with staphylococcal protein A coupled to Sepharose, indicating that they were not IgG of the major subclasses 1, 2, 4. Further characterization of the serum inhibitors was not attempted, because a previous report (28) showed that they were heterogeneous and present in the macroglobulin, gamma globulin, and albumin components of serum.
After TSH was immunoaffinity-purified from serum, it showed a potent stimulatory activity. The dose-response curves of immunoreactive serum TSH, obtained from one of the patients with primary hypothyroidism (No. 12) before (12b) and after (12a) immunopurification, are depicted in Fig. 2 A. In Fig.  2 B, additional dose-response curves of representative immunoaffinity purified samples are shown. Two hypothyroid patients demonstrating potent stimulatory activity (Nos. 8 and 9), one subclinical hypothyroid patient demonstrating weak stimulatory activity (No. 5), and one euthyroid control demonstrating no stimulatory activity above the limit of detection (No. 4) are illustrated. All immunoaffinity-purified samples with significant stimulatory activity showed a parallelism to the 2nd IRP reference preparation that was used as standard in our FRTL-5 bioassay.
In four patients (Nos. 7, 9, 10, 12) the bioactivity was also tested for the TSH that did not bind to the column during immunopurification, as well as for the TSH that appeared in the 6 M wash fraction. No stimulation of cAMP was seen in either ofthese fractions (data not shown). The unbound TSH produced a cAMP response lower than the baseline, most likely related to serum inhibitory factors, as described by Rapoport and Adams (28) , whereas the lack of stimulation by the fraction eluted with 6 M guanidine could be accounted for by either a tightly bound form of TSH with low activity and/or denaturation of the TSH molecule at high salt concentration. We have previously shown TSH (MU/0.5 ml) 1 no irreversible denaturation effects ofbrief exposure to guanidine at concentrations below 3 M at 4VC (10). TSH, which bound to the immunoaffinity column during purification and eluted with brief exposure to 3 M guanidine, varied in B/I ratios from < 0.25 to 1.21 among four euthyroid subjects and eight mildly to severely hypothyroid patients (Table  I ). An inverse correlation was found between the B/I ratios of immunopurified basal TSH and the serum FT4 (r = -0.7237; P < 0.01), T4 (r = -0.6650; P < 0.05), and T3 (r = -0.6382; P < 0.05) concentrations, in all measured samples (Fig. 3, A-C) . Moreover, a direct correlation was found between the B/I ratios ofimmunopurified TSH and the serum TSH (r = 0.8355; P < 0.001) concentration (Fig. 3 D) . For In three hypothyroid patients B/I ratios of immunopurified TSH were evaluated in samples obtained before and after acute stimulation by TRH (Table II) . The B/I ratio of the released material did not significantly differ from that of basal TSH, despite major changes in serum TSH concentration. This clearly indicates the consistency of TSH B/I ratios in a given patient, thus ruling out that different B/I ratios were related to assay artifacts such as increased stability of TSH at higher concentrations.
In the radioimmunoassay, linearized TSH dose-response curves from nonimmunopurified hTSH Calbiochem reference preparation and from euthyroid and hypothyroid subjects before and after purification did not differ significantly from those of the 2nd IRP used as a standard when tested for parallelism (Table III) .
Discussion
In the present study we have compared the B/I ratios of circulating TSH obtained after immunoaffinity purification of serum from euthyroid, mildly hypothyroid, and severely hypothyroid subjects. We then correlated these ratios to the serum levels of both TSH and thyroid hormones in each subject. The B/I ratios correlated directly with serum basal values of TSH (P < 0.001) and inversely with FT4 (P < 0.01), T4 (P < 0.05), and T3 (P < 0.05), thereby indicating an inverse relationship between the metabolic status of an individual and the quality of circulating TSH. The existence of a significant correlation between the bioactivity of a pituitary hormone and its target organ's serum hormone concentration has not previously been described. The results are, however, generally in agreement with findings concerning other pituitary glycoprotein hormones, because increased in vitro bioactivity for luteinizing hormone (LH) has been re- ported in postmenopausal compared with premenopausal women (29) and this increased bioactivity can be reduced by estrogen therapy (30) . Other than our previous studies (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , the only reports concerning TSH bioactivity and B/I ratios in normal or diseased humans used the cAMP activation assay in primary cultures of dog thyroid cells (28) and the cytochemical assay (6) (7) (8) (31) , it has recently been demonstrated that thyroid hormones also act at a pretranslational level by direct inhibition of the transcription of TSH a-and ,3-subunit genes (32, 33 (35) . We have also demonstrated that chemical deglycosylation of TSH greatly reduces its bioactivity and produces a form that acts as a competitive antagonist (36) . Since thyroid hormones have been shown to affect TSH glycosylation in rodents (37, 38) , our present study suggests that they may also affect posttranslational TSH carbohydrate processing in man, either by a direct effect on the thyrotrophs or indirectly through TRH release and secretion.
The metabolic clearance rate of human FSH derived from postmenopausal women was found to be lower than that ofFSH obtained from premenopausal women (39) . Similarly, the TSH derived from hypothyroid rats has also been shown to have a lower clearance rate than that derived from normal rats (40). There may, therefore, be selective peripheral metabolism ofcertain circulating forms ofTSH to preserve biologically active TSH forms in the circulation of hypothyroid subjects. This hypothesis is supported by data showing that TSH secreted from pituitaries of hypothyroid rats in vitro has a similar bioactivity to that from normal rats (41).
We did not observe any significant change in biopotency of TSH 20-180 min after acute TRH stimulation in three patients with severe primary hypothyroidism. In contrast, acute TRH stimulation in patients with central hypothyroidism appeared to release somewhat more bioactive TSH forms, an effect more obvious after chronic TRH stimulation ( 12) . It is reasonable to assume that primary hypothyroid patients already are subjected to a chronic TRH stimulation via physiological feedback mechanism and therefore cannot respond to further stimulation. In central hypothyroidism with presumable TRH deficiency, an acute TRH injection probably releases prestored TSH forms of higher biopotency but chronic TRH stimulation may be required to significantly induce the formation of more bioactive TSH. In animal experiments it has, moreover, been shown that TRH regulation of TSH glycosylation is a time-dependent event, appearing at -6 h in hypothyroid rats and at 24 h in euthyroid animals (42) .
A change in B/I ratios during different physiological or pathophysiological conditions could logically reflect changes in either B or I. Although usually reflective ofchanges in B, a change in I was recently demonstrated for certain forms of LH, which were nonparallel to the standard LH in radioimmunoassay (43) . However, in the current investigation the parallel slopes noted in our TSH radioimmunoassay for different dilutions of unpurified and purified samples from euthyroid and hypothyroid subjects, as well as for nonimmunopurified human TSH Calbiochem reference preparation, suggest a "true" change in bioactivity. It has, moreover, been demonstrated that purified TSH does not show any change in I after deglycosylation, in spite of major changes in B (36) . Therefore, it appears that the polyclonal antiserum used in our current TSH radioimmunoassay is unlikely to be sensitive to 
